Biogen Inc NASDAQ:BIIB Price, Chart, News & Insight

Biogen Rises 1% as Revenue Growth Returns and 2026 EPS Guidance Improves

Biogen (NASDAQ: BIIB) shares rose about 1% after the company reported double-digit third-quarter revenue growth, strong momentum across its Growth Portfolio and a higher lower end of full-year EPS guidance.

Third-quarter revenue increased 11% year over year to $2.80 billion, while Growth Portfolio revenue surged 49% to $1.26 billion and represented 63% of Core Pharmaceutical revenue. Key products included SPINRAZA, up 23%, LEQEMBI, up 67%, SKYCLARYS, up 34%, and ZURZUVAE, up 53%.

Reported earnings were pressured by transaction-related expenses. GAAP EPS was a loss of $0.14, while non-GAAP EPS fell to $2.62 from $4.81 a year earlier. Results included $284 million of acquired IPR&D, upfront and milestone expenses, primarily tied to the RayThera acquisition.

The Apellis portfolio also contributed strongly in its first full quarter under Biogen. SYFOVRE revenue rose 27% to $191 million, while EMPAVELI nearly doubled to $52 million. However, legacy multiple sclerosis product revenue declined 13%, and biosimilars revenue fell 16%.

Biogen raised the lower end of its 2026 reported non-GAAP EPS guidance to $12.20-$13.00 from $12.00-$13.00, citing underlying business strength and better-than-expected dilution from the Apellis acquisition. Full-year revenue is expected to grow at a mid-single-digit rate.

The 1% gain appears to reflect renewed confidence in Biogen’s growth portfolio and improved guidance, which outweighed lower year-over-year EPS and elevated acquisition-related expenses.

💬

WS Investor 10-28-26

Biogen Stock Rises After Barclays Raises Price Target Despite Maintaining Equal-Weight Rating

Biogen (NASDAQ: BIIB) shares were up about 4.6% on Wednesday after Barclays raised its price target on the biotechnology company to **$200 from $185**, while maintaining its **Equal Weight** rating.

The higher target price reflects improved confidence in Biogen's valuation and business outlook, although Barclays stopped short of becoming more bullish on the stock. An Equal Weight rating generally indicates the analyst expects the shares to perform roughly in line with the broader market or industry peers.

The revised $200 price target represents an increase of approximately 8% from the previous target and suggests additional upside from recent trading levels. Investors appeared to welcome the more optimistic valuation, pushing the stock higher in early trading.

The target increase comes as Biogen continues to execute on its strategy of expanding beyond its traditional multiple sclerosis franchise, with growing contributions from rare disease and neuroscience therapies. Investors are also closely watching the commercial performance of the company's Alzheimer's portfolio and pipeline developments, which remain key drivers of long-term growth expectations.

While Barclays' decision to raise its price target signals increased confidence in Biogen's prospects, the unchanged Equal Weight rating suggests the firm believes much of the company's improving outlook is already reflected in the stock price.

💬

The Investor 07-29-26

Biogen (BIIB) Stock Advances After Truist Upgrades Shares to Buy and Raises Price Target

Biogen (NASDAQ: BIIB) shares gained about 1.6% after Truist Financial upgraded the biotechnology company to Buy from Hold and raised its price target to $235 from $190.

The upgrade reflects growing confidence in Biogen's long-term growth outlook as investors look beyond legacy multiple sclerosis products and focus on the company's expanding neuroscience portfolio. Recent progress across Alzheimer's disease, rare diseases, and other neurological treatments has strengthened expectations for future revenue growth.

Biogen has also continued to improve its financial profile through disciplined cost management while advancing newer therapies that could diversify its earnings base over the coming years.

Key factors supporting the stock include:

* Truist Financial upgraded Biogen to Buy from Hold.
* The firm raised its price target to $235 from $190.
* Investors remain optimistic about the company's expanding neuroscience pipeline and long-term growth opportunities.
* Continued portfolio diversification and operational discipline are expected to support future earnings.

The analyst upgrade reinforced positive sentiment toward Biogen's evolving business strategy, helping lift the stock during the session.

💬

WS Investor 07-13-26

Biogen Inc disclosed in a regulatory filing that its fourth-quarter 2025 results will include a significant charge related to acquired in-process research and development, upfront, and milestone expenses. The company said it expects a pre-tax expense of approximately $222 million, which is estimated to reduce both GAAP and non-GAAP earnings by about $1.26 per diluted share for the quarter.

Biogen noted that these costs stem from collaboration and licensing agreements, including upfront and milestone payments and, where applicable, premiums on equity securities or asset acquisitions. The company does not forecast such expenses due to uncertainty around their timing and size. Biogen cautioned that its fourth-quarter 2025 financial results have not yet been finalized and remain subject to closing procedures, meaning final figures could differ from these preliminary estimates.

💬

WS Investor 01-14-26

Biogen Posts Strong Q3 Results, Raises 2025 Outlook on Launch Product Momentum

Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3% year over year, with GAAP diluted EPS rising 19% to $3.17 and non-GAAP EPS up 18% to $4.81. Growth was driven by a 67% surge in newer products, including LEQEMBI, SKYCLARYS, and ZURZUVAE. Alzheimer’s drug LEQEMBI generated $121 million in global sales, while SKYCLARYS reached $133 million and ZURZUVAE $55 million. The MS franchise grew 1% on U.S. strength in VUMERITY. Biogen advanced key pipeline programs, including FDA resubmission for high-dose SPINRAZA and full enrollment of two Phase 3 litifilimab lupus studies. The company raised its 2025 non-GAAP EPS guidance to $14.50–$15.00 and now expects total revenue to be flat to up 1% year over year.

💬

Global Finance News 10-30-25

Biogen Issues $1.75 Billion in Senior Notes to Refinance 2025 Debt

Biogen Inc. has completed a $1.75 billion offering of senior unsecured notes, consisting of $400 million in 5.050% notes due 2031, $650 million in 5.750% notes due 2035, and $700 million in 6.450% notes due 2055. The issuance was managed by BofA Securities, Citigroup, and J.P. Morgan as lead underwriters.

Proceeds from the sale will be used to retire Biogen’s outstanding 4.050% senior notes maturing in 2025, which carry the same principal amount. Any remaining funds will be directed toward general corporate purposes and working capital.

The new notes are callable at the company’s discretion and include provisions for repurchase at 101% of par in the event of a qualifying change in control. The issuance strengthens Biogen’s debt profile by locking in longer-term financing while providing flexibility for future operations.

💬

M

ME NEWS 05-13-25

Biogen Q1 2025 Earnings

Biogen delivered stronger-than-expected revenue in the first quarter of 2025, driven by growing contributions from launch products and rare disease therapies. However, net income and earnings per share declined due to a $165 million upfront payment related to a new collaboration.

Key highlights:

- Total revenue was $2.43 billion, up 6 percent year-over-year (up 8 percent at constant currency).
- GAAP net income was $240.5 million or $1.64 per diluted share (down from $393.4 million or $2.70 EPS in Q1 2024).
- Non-GAAP net income was $443.2 million or $3.02 per diluted share (down from $535.0 million or $3.67 EPS).
- EPS includes a roughly $0.95 negative impact from the $165 million upfront transaction with Stoke Therapeutics for zorevunersen.
- Free cash flow was $222 million.

Segment details:

- MS revenue declined 11 percent (10 percent at constant currency) to $953 million.
- Rare disease revenue grew 33 percent (36 percent at constant currency) to $563 million, led by SPINRAZA, SKYCLARYS, and QALSODY.
- Biosimilars revenue dropped 8 percent to $181 million.
- Alzheimer’s collaboration revenue rose to $33 million from just $3 million last year, driven by LEQEMBI.
- Contract manufacturing and royalty revenue grew 61 percent to $293 million.

Expenses:

- GAAP R&D expense was $434 million; Non-GAAP R&D expense was $427 million.
- SG&A expense was steady at $573 million GAAP and $572 million Non-GAAP.
- Acquired IPR&D and milestone payments surged to $201 million, including $165 million to Stoke and a $35 million milestone to MorphoSys.
- The effective tax rate rose to 22.7 percent GAAP (vs. 15.4 percent in Q1 2024); Non-GAAP rate was 19.4 percent.

Balance sheet and cash flow:

- Biogen ended the quarter with $2.6 billion in cash and $6.3 billion in total debt, for net debt of $3.7 billion.
- Operating cash flow was $259 million.

2025 outlook:

- Updated Non-GAAP EPS guidance is $14.50 to $15.50 (down from $15.25–$16.25), reflecting the Stoke payment and some FX benefit.
- Biogen expects a mid-single-digit percentage decline in total revenue for the full year.
- Non-GAAP R&D and SG&A expenses combined are expected to total around $3.9 billion.
- The Fit for Growth program is on track to generate $1 billion in gross savings by year-end 2025.

💬

Global Finance News 05-01-25

Biogen Inc. has announced significant changes in its executive team through a recent Form 8-K filing with the SEC. Effective March 1, 2025, Sean Godbout will be appointed as the Vice President, Chief Accounting Officer, and Global Corporate Controller. Concurrently, he will assume the role of the company's principal accounting officer, succeeding Robin Kramer who has been appointed as Biogen's Chief Financial Officer following the retirement of Michael McDonnell on the same date.

Sean Godbout, who has been with Biogen since 2007 and served as Global Corporate Controller since October 2023, brings extensive experience to his new role. Prior to joining Biogen, he held positions at PricewaterhouseCoopers LLP. He holds a B.S. from Cornell University and an M.S. in Accounting and MBA from Northeastern University. Mr. Godbout is also a Certified Public Accountant in Massachusetts.

As part of his compensation, Mr. Godbout will have a base salary of $400,000, with eligibility for an annual bonus targeted at 40% of his base salary. His long-term incentive grant for 2025 will align with the company's LTI plans and guidelines at the time of the grant. Additionally, under Biogen's executive severance plan for Vice Presidents, Mr. Godbout will be entitled to severance benefits including a lump sum payment in certain termination scenarios and continued medical and dental insurance benefits if applicable.

These executive transitions are part of Biogen's strategic leadership adjustments aimed at sustaining its growth and operational efficiency.

💬

European Investor 01-15-25

NASDAQ:BIIBFollow

NASDAQ:BIIB